胃腺癌患者病变组织中PPARγ和PGC-1表达水平与临床病理特征的关系
|
摘要
目的检测PPARγ与PGC-1在胃腺癌演变各阶段过程中的表达,探讨PPARγ和PGC-1在胃癌发生中的作用及其临床病理意义。方法选择2011年1月～2016年9月荆州市第二人民医院收集的135例胃腺癌组织标本、52例正常胃黏膜组织标本以及19例慢性萎缩性胃炎、31例肠上皮化生、16例不典型增生等不同程度癌前病变组织标本。采用免疫组化方法,检测PPARγ、PGC-1在各组标本中的表达情况,分析正常胃黏膜、癌前病变、胃腺癌组织中PPARγ、PGC-1的阳性表达差异以及PPARγ、PGC-1表达之间的相关性,并分析其表达与胃癌病理特征的关系。结果 PPARγ及PGC-1在胃癌组织中的阳性表达率较癌前病变组织及正常胃黏膜组织中的表达降低,差异均有统计学意义(P<0.05)。135例胃癌中,PPARγ与PGC-1的表达成显著正相关(r=0.956,P<0.05);PPARγ、PGC-1阳性表达随着胃癌组织分化程度的降低而降低(P<0.05),PPARγ、PGC-1阳性表达与患者的Borrmann分型、Lauren分型、组织分化程度及TNM分期有关(P<0.05)。PPARγ、PGC-1阳性表达与患者的性别、年龄、淋巴结转移与否无相关性(P>0.05)。结论 PPARγ、PGC-1表达与胃癌发生、发展关系密切,检测PPARγ、PGC-1表达水平有助于预测胃癌的进展。
Objective To detect the expression of PPARγ and PGC-1 of the evolution of gastric adenocarcinoma in different stages, and to explore the role of PPARγ and PGC-1 in the development of gastric cancer and its clinicopathological significance. Methods From January 2011 to September 2016, 135 gastric adenocarcinoma tissue specimens, 52 normal gastric mucosa tissue specimens, 19 cases of chronic atrophic gastritis, 31 cases of intestinal metaplasia and 16 cases of atypical hyperplasia were collected from the Second People′ s Hospital of Jingzhou City. The expression of PPARγ and PGC-1 was examined by immunohistochemical method. The difference of positive expression of PPARγand PGC-1 in normal gastric mucosa, precancerous lesions and gastric adenocarcinoma were analyzed, and the correlation between the expression of PPARγ and PGC-1 and the pathological characteristics of gastric cancer were analyzed.Results The positive expression rates of PPARγ and PGC-1 in the gastric cancer tissues were lower than those in the precancerous lesion tissues and the normal gastric mucosa tissues, and the difference was statistically significant(P<0.05). In 135 cases of gastric adenocarcinoma, the expression of PPARγ was positively correlated with PGC-1 expression(r=0.956, P<0.05). The expression levels of PPARγ and PGC-1 were decreased with the lower ranked differentiation of gastric cancer(P<0.05). The expression levels of PPARγ and PGC-1 were closely associated with the Borrmann type, Lauren classification, the histological differentiation and TNM tumor stage(P<0.05). However, there was no significant association between the expression of PPARγ and PGC-1 and the gender, age and lymph node metastasis(P>0.05). Conclusion The expression levels of PPAR and PGC-1 are closely related to the occurrence and development of gastric cancer. Monitoring the expression levels of PPARγ and PGC-1 may be helpful to predict the development and progression of gastric cancer.
Objective To detect the expression of PPARγ and PGC-1 of the evolution of gastric adenocarcinoma in different stages, and to explore the role of PPARγ and PGC-1 in the development of gastric cancer and its clinicopathological significance. Methods From January 2011 to September 2016, 135 gastric adenocarcinoma tissue specimens, 52 normal gastric mucosa tissue specimens, 19 cases of chronic atrophic gastritis, 31 cases of intestinal metaplasia and 16 cases of atypical hyperplasia were collected from the Second People′ s Hospital of Jingzhou City. The expression of PPARγ and PGC-1 was examined by immunohistochemical method. The difference of positive expression of PPARγand PGC-1 in normal gastric mucosa, precancerous lesions and gastric adenocarcinoma were analyzed, and the correlation between the expression of PPARγ and PGC-1 and the pathological characteristics of gastric cancer were analyzed.Results The positive expression rates of PPARγ and PGC-1 in the gastric cancer tissues were lower than those in the precancerous lesion tissues and the normal gastric mucosa tissues, and the difference was statistically significant(P<0.05). In 135 cases of gastric adenocarcinoma, the expression of PPARγ was positively correlated with PGC-1 expression(r=0.956, P<0.05). The expression levels of PPARγ and PGC-1 were decreased with the lower ranked differentiation of gastric cancer(P<0.05). The expression levels of PPARγ and PGC-1 were closely associated with the Borrmann type, Lauren classification, the histological differentiation and TNM tumor stage(P<0.05). However, there was no significant association between the expression of PPARγ and PGC-1 and the gender, age and lymph node metastasis(P>0.05). Conclusion The expression levels of PPAR and PGC-1 are closely related to the occurrence and development of gastric cancer. Monitoring the expression levels of PPARγ and PGC-1 may be helpful to predict the development and progression of gastric cancer.
引文
[1]Chen HH,Chang PC,Wey SP,et al.Therapeutic effects of honokiol on motor impairment in hemiparkinsonian mice are associated with reversing neurodegen eration and targeting PPARγregulation[J].Biomed Pharmacother,2018,7(95):254-262.
[2]Rohini A,Neeraj A,Harish K,et al.Norbixin,an apocarotenoid derivative activates PPARγin cardiometabolic syndrome:validation by in silico and in vivo experimental assessment[J].Life Sci,2018,8(1):69-77.
[3]Chen YY,Yan Y,Zhao Z,et al.Bofutsushosan ameliorates obesity in mice through modulating PGC-1αexpression in brown adipose tissues[J].Chin J Nat Med,2016,14(6):449-456.
[4]Yang X,Xu S,Qian Y,et al.Resveratrol regulates microglia M1/M2 polarization via PGC-1 in conditions of neuroin-flammatory injury[J].Brain Behav Immun,2017,64:162-172.
[5]Katsouri L,Lim YM,Brondrath K,et al.PPARγ-coactivator-1 gene transfer reduces neuronal loss and amyloid-β generation by reducingβ-secretase in an Alzheimer′s disease model[J].Proc Natl Acad Sci USA,2016,113(43):12 292-12 297.
[6]顿琳.KISS-1和PPARγ在食管鳞癌组织中的表达及其临床意义[D].石家庄:河北医科大学,2017.
[7]Terashita Y,Sasaki H,Haruki N,et al.Decreased c gene expression was correlated with poor prognosis in patients with esophageal cancer[J].Jpn J Clin Oncol,2002,32(7):238-243.
[8]邵飞,张晓文,沈山梅.BRAF、TERTp、RAS、RET/PTC、PAX8/PPAR在甲状腺癌中的研究进展[J].医学综述,2018,24(7):1318-1323.
[9]梁少强,涂青松,黄荣,等.宫颈癌中PPARγ的表达及其意义[J].中国医药科学,2012,2(15):18-19.
[10]Simone P,Mirko T,Sara T,et al.Peroxisome proliferator activated receptors at the crossroad of obesity,diabetes,and pancreatic cancer[J].World J Gastroenterol,2018,35(9):2441-2459.
[11]Davidson B,Hadar R,Stavens HT,et al.Expression of the peroxisome proliferator-activated receptors-alhpa,-beta,and-gamma in ovarian carcinoma effusions is associated with poor chemorespones and short survival[J].Hum Pathol,2009,40(5):705-713.
[12]Chen WQ,Zhang RS,Zhang SW,et al.Report of cancer incidence and mortality in China 2012[J].China J Cancer Res,2012,24(3):171-180.
[13]吴东,李丽霞,袁亚连,等.SIRT1与PPARγ在非小细胞肺癌组织中的表达及其临床意义[J].广东医科大学学报,2017,35(1):1-4.
[14]Yun SH,Roh MS,Jeong JS,et al.Peroxisome proliferatoractivated receptorγcoactivator-1αis a predictor of lymph node metastasis and poor prognosis in human colorectal cancer[J].Ann Diagn Pathol,2018,4:11-16.
[15]韦美德,董家书,周格琛,等.乳腺癌患者血清PPAR-γ基因甲基化qPCR检测及临床意义[J].分子诊断与治疗杂志,2018,10(4):241-245.
[16]廖山婴,朱小波,王蓓蓓,等.PPARγ、PTEN、Akt在胃癌中的表达及其与胃癌生物学行为的关系[J].新医学,2014,45(6):394-398.
[17]Xi YR,Dong YZ,Fang G,et al.PPARγsuppressed Wnt/β-catenin signaling pathway and its downstream effector SOX9expression in gastric cancer cells[J].Med Oncol,2015,32(4):522-529.
[18]Grytting VS,Olderbo BP,Holme JA,et al.Dinbutyl phthalate modifies PMA-induced macrophage differentiation of THP-1 monocytes via PPARγ[J].Toxicol In Vitro,2019,54:168-177.
[2]Rohini A,Neeraj A,Harish K,et al.Norbixin,an apocarotenoid derivative activates PPARγin cardiometabolic syndrome:validation by in silico and in vivo experimental assessment[J].Life Sci,2018,8(1):69-77.
[3]Chen YY,Yan Y,Zhao Z,et al.Bofutsushosan ameliorates obesity in mice through modulating PGC-1αexpression in brown adipose tissues[J].Chin J Nat Med,2016,14(6):449-456.
[4]Yang X,Xu S,Qian Y,et al.Resveratrol regulates microglia M1/M2 polarization via PGC-1 in conditions of neuroin-flammatory injury[J].Brain Behav Immun,2017,64:162-172.
[5]Katsouri L,Lim YM,Brondrath K,et al.PPARγ-coactivator-1 gene transfer reduces neuronal loss and amyloid-β generation by reducingβ-secretase in an Alzheimer′s disease model[J].Proc Natl Acad Sci USA,2016,113(43):12 292-12 297.
[6]顿琳.KISS-1和PPARγ在食管鳞癌组织中的表达及其临床意义[D].石家庄:河北医科大学,2017.
[7]Terashita Y,Sasaki H,Haruki N,et al.Decreased c gene expression was correlated with poor prognosis in patients with esophageal cancer[J].Jpn J Clin Oncol,2002,32(7):238-243.
[8]邵飞,张晓文,沈山梅.BRAF、TERTp、RAS、RET/PTC、PAX8/PPAR在甲状腺癌中的研究进展[J].医学综述,2018,24(7):1318-1323.
[9]梁少强,涂青松,黄荣,等.宫颈癌中PPARγ的表达及其意义[J].中国医药科学,2012,2(15):18-19.
[10]Simone P,Mirko T,Sara T,et al.Peroxisome proliferator activated receptors at the crossroad of obesity,diabetes,and pancreatic cancer[J].World J Gastroenterol,2018,35(9):2441-2459.
[11]Davidson B,Hadar R,Stavens HT,et al.Expression of the peroxisome proliferator-activated receptors-alhpa,-beta,and-gamma in ovarian carcinoma effusions is associated with poor chemorespones and short survival[J].Hum Pathol,2009,40(5):705-713.
[12]Chen WQ,Zhang RS,Zhang SW,et al.Report of cancer incidence and mortality in China 2012[J].China J Cancer Res,2012,24(3):171-180.
[13]吴东,李丽霞,袁亚连,等.SIRT1与PPARγ在非小细胞肺癌组织中的表达及其临床意义[J].广东医科大学学报,2017,35(1):1-4.
[14]Yun SH,Roh MS,Jeong JS,et al.Peroxisome proliferatoractivated receptorγcoactivator-1αis a predictor of lymph node metastasis and poor prognosis in human colorectal cancer[J].Ann Diagn Pathol,2018,4:11-16.
[15]韦美德,董家书,周格琛,等.乳腺癌患者血清PPAR-γ基因甲基化qPCR检测及临床意义[J].分子诊断与治疗杂志,2018,10(4):241-245.
[16]廖山婴,朱小波,王蓓蓓,等.PPARγ、PTEN、Akt在胃癌中的表达及其与胃癌生物学行为的关系[J].新医学,2014,45(6):394-398.
[17]Xi YR,Dong YZ,Fang G,et al.PPARγsuppressed Wnt/β-catenin signaling pathway and its downstream effector SOX9expression in gastric cancer cells[J].Med Oncol,2015,32(4):522-529.
[18]Grytting VS,Olderbo BP,Holme JA,et al.Dinbutyl phthalate modifies PMA-induced macrophage differentiation of THP-1 monocytes via PPARγ[J].Toxicol In Vitro,2019,54:168-177.